Clinical Trials Update: June 22, 2007

Multiple SclerosisGeneralized Anxiety Disorder (GAD)Rheumatoid Arthritis

(HealthDay News) -- Here are the latest clinical trials, courtesy of CenterWatch:

Multiple Sclerosis

This is a phase II study for people with multiple sclerosis who have cognitive impairment. Volunteers 18-64 who have at least a 9th grade education and a diagnosis of MS (relapsing remitting or secondary progressive) may be eligible. Candidates will be ineligible if they have memory deficits caused by significant neurological/psychological disorders, major depressive disorder, or are taking certain medications, including tricyclic antidepressants, antipsychotics, Strattera, or CNS stimulants.

The research sites are located across the United States.

More Information

Please see http://www.centerwatch.com/patient/studies/cat102.html.

-----

Generalized Anxiety Disorder (GAD)

This is an 11-week study to evaluate the safety and effectiveness of an investigational drug in treating generalized anxiety disorder (GAD). Candidates 66 or older may qualify who have a clinical diagnosis of GAD, and do not have a current episode of major depression, a history of inadequate response to two or more classes of anti-depressants during previous depressive episode(s), or a history of stroke.

The research sites are located across the United States.

More Information

Please see http://www.centerwatch.com/patient/studies/cat414.html.

-----

Rheumatoid Arthritis

If you are having an inadequate response to methotrexate therapy for your rheumatoid arthritis, you may qualify for this study of an investigational medication. Participants must be 18 or older and diagnosed with RA. Compensation of up to $250 is available to those who qualify.

The research site is in Scottsdale, Ariz.

More Information

Please see http://www.centerwatch.com/patient/studies/cat132.html.

-----

Copyright 2007 CenterWatch. All rights reserved.

Related Stories

No stories found.
logo
www.healthday.com